JOIN4ATMP Annual Meeting 2025: Building the legacy of Advanced Therapies in Europe

On 11-12 November 2025 the JOIN4ATMP consortium gathered in Barcelona for its second Annual meeting, hosted by the Vall d’Hebron Institute of Oncology (VHIO). Partners from across Europe met to review progress, exchange insights and chart the next steps towards making Advanced Therapy Medicinal Products (ATMPs) more accessible for patients across Europe.

The meeting opened with reflections on the consortium’s achievements during the past year. Partners presented concrete progress on mapping regulatory, clinical and manufacturing hurdles for ATMP development, and on formulating recommendations to improve the European landscape. The discussion highlighted how JOIN4ATMP’s collaborative model is already fostering a pan-European network of hospitals and research institutions committed to accelerating ATMP translation.

A dedicated “JOIN4ATMP Heritage” session focused on the project’s long-term vision: ensuring that its outcomes have lasting impact beyond the project lifetime. Partners explored how to consolidate JOIN4ATMP’s growing knowledge base into actionable recommendations and white papers, including contributions from preclinical and clinical research, manufacturing, regulation and patient engagement. The debate emphasised the consortium’s unique position to influence future EU policy and the need to continue shaping Europe’s ATMP ecosystem through scientific evidence, cross-sector dialogue and sustainability planning.

In the same spirit, some JOIN4ATMP partners also participated in the VHIO–BBVA Symposium on “Building bridges between advanced therapies and clinical practice”, held the following two days. Findings and perspectives from JOIN4ATMP were presented to a wider scientific audience, reinforcing the project’s commitment to connecting project’s outcome with clinical implementation.

As the consortium enters its final project year, discussions in Barcelona marked a turning point. JOIN4ATMP is moving from analysis to action and legacy-building: transforming the lessons learned into tangible outputs such as recommendations, publications and strategic frameworks that will support ATMP development, regulation and equitable access across Europe.

“JOIN4ATMP is creating the blueprint for a sustainable, collaborative approach to bring advanced therapies closer to patients,” one partner summarised during the closing session.

With one year remaining, the consortium looks ahead to strengthening synergies across Europe and ensuring that JOIN4ATMP’s impact continues well beyond its formal end.